AI-researched · adversarially reviewed · human-checked · corrections public
BEFORE YOU READ — HOW DO YOU RULE?
The Verdict
For people with type 2 diabetes, and for people with obesity plus heart-disease risk, GLP-1 drugs are the real thing: roughly 15–20% body-weight loss in trials and — rare for any weight drug — proven reductions in heart attacks and strokes. The catches are just as real: gastrointestinal misery for many, muscle inside the lost weight, most of the weight returning when you stop, a price built for shareholders, and a market now stretching the drug far beyond the people it was tested on.
Works, with catches
STRONG EVIDENCE
§ What it actually does
Where the evidence says yes
strongProduces large weight loss in people with obesity: semaglutide averaged ~15% of body weight over 68 weeks; tirzepatide ~20% — levels previously seen only with surgery.
strongReduces heart attacks and strokes in people with obesity and existing cardiovascular disease (SELECT trial) — the first weight drug ever to show this.
strongControls blood sugar in type 2 diabetes; that was its original, well-proven job.
moderateLikely slows kidney-disease progression in diabetics at risk (FLOW trial stopped early for benefit).
weakMay reduce alcohol craving and other compulsive consumption — early trials are intriguing and unfinished.
§ What it doesn't do
Where the marketing outruns the data
strongDoes not cure anything: stop the drug and most of the weight returns — participants regained roughly two-thirds of lost weight within a year of stopping. The honest model is a chronic treatment, priced like a subscription to your own body.
moderateDoes not make the lost weight all fat: a meaningful fraction is lean mass/muscle — a real concern for older users, and the reason resistance training and protein matter alongside it.
noneThere is no trial evidence for the cosmetic last-5-kg user — the trials enrolled people with obesity or diabetes, not people chasing a wedding dress size.
contradicted"Well tolerated" marketing understates reality: nausea, vomiting, constipation and diarrhea are very common; a substantial minority quit because of them.
§ The Money Map
Who profits, stage by stage
The manufacturersNovo Nordisk and Eli Lilly earn tens of billions per year from GLP-1s; Novo became Europe's most valuable company on the back of semaglutide. Every landmark trial here was manufacturer-funded (COI-flagged below) — rigorously run and FDA-audited, but the funding line belongs in view.
The priceUS list price roughly $1,000/month; the same pens sell for a fraction of that in Europe and India. The price is what the market bears, not what production costs.
The prescribing boomTelehealth mills prescribe after a questionnaire; med-spas and compounding pharmacies sell "semaglutide" of variable provenance in a regulatory gray zone the FDA keeps warning about.
The influencersCelebrity before/afters and #Ozempic content sell the cosmetic use the trials never tested — no one in that pipeline is paid to mention muscle loss or regain.
This pageNo pharma money, no telehealth affiliate links, no supplement "alternatives" for sale. See "How we make money."
§ The other side
The strongest case against this verdict
The strongest case for deeper skepticism than our verdict: these drugs are a decade old at population scale, and we are medicating the food environment instead of fixing it. Long-term effects of chronic GLP-1 use across tens of millions of healthy-ish people are simply unknown — rodent thyroid tumors, rare pancreatitis and gastroparesis signals, and the lean-mass question deserve more respect than the gold-rush is giving them. The regain data means we may be enrolling a generation into a $12,000-a-year dependency whose exit door leads back to the starting weight. A society that needed an injection to survive its own food supply has treated a symptom and called it a cure.
§ Symmetric harms
Harms of using it — and of avoiding it
If you use it
Very common GI effects (nausea, vomiting, constipation); a meaningful minority discontinue because of them.
Rare but real: pancreatitis, gastroparesis (now in litigation), gallbladder disease; rapid weight loss itself raises gallstone risk.
Muscle loss within the lost weight — worst deal for older adults.
The exit problem: stopping usually means regaining; few users are told this at the point of prescription.
Financial: at US prices, years of use costs more than most cars.
If you avoid it
For type 2 diabetics and people with obesity + heart disease: refusing a drug with proven cardiovascular benefit leaves real, countable risk on the table.
For people with severe obesity: the "just diet" alternative has a decades-long documented failure rate; moralizing it has saved no one.
§ The Minority Report
Who gets hurt when it goes right for everyone else
The harms concentrate in identifiable groups — mostly people the trials never enrolled.
People with a personal/family history of medullary thyroid carcinoma or MEN2: formally contraindicated (rodent tumor signal).
People with a history of pancreatitis or gastroparesis: the rare severe GI outcomes cluster here.
Older adults and the already-lean: muscle loss hits hardest where reserve is lowest.
People with eating disorders: questionnaire-based telehealth happily supplies a powerful appetite suppressant to exactly the people it can hurt most.
Cosmetic users buying gray-market "compounded semaglutide": dosing errors and unverified vials — the FDA has logged hundreds of adverse-event reports.
How to tell if you might be in this group: Ask: do the trial populations include someone like me (BMI, diabetes, heart risk)? Any thyroid-cancer family history? Any pancreatitis? Am I prepared for the exit problem — what is my plan for the day I stop?
§ The alternatives ledger
Everything else, judged by the same standards
strong
Bariatric surgery Still the heavyweight: larger, more durable weight loss and long-term mortality benefit in observational data. More invasive, more upfront risk.
moderate
Structured diet + resistance training Average results are modest and regain is common — but it is the only option that adds muscle instead of subtracting it, and it compounds with everything else.
strong
Metformin and older diabetes drugs For glucose control: cheap, proven, decades of safety data. Not a weight-loss tool of this magnitude.
none
"Natural Ozempic" (berberine et al.) There is no evidence that any supplement replicates GLP-1 effects, despite an entire TikTok economy claiming otherwise.
§ Take it to a human
Questions for your doctor
Do I match the populations in the trials — or am I a cosmetic user extrapolating?
What is the plan for muscle: protein target and resistance training alongside the drug?
What is the exit strategy — do we taper, and what happens to my weight and my budget in year 3?
Given my history (thyroid, pancreas, gut), am I in any of the excluded groups?
Effects of 10–20 years of continuous use in non-diabetic populations.
Whether the alcohol/compulsion findings hold up in large trials.
What fraction of real-world users keep the cardiovascular benefit seen in trial-adherent patients.
§ Corrections
Updates & corrections — public, dated, proud
No corrections yet. Found an error? Challenge it — substantiated challenges are corrected within 48 hours and logged here permanently. Submit a challenge →
§ We dissect ourselves too
How WE make money
This pageNothing on this page: no pharma advertising, no telehealth referral fees, no supplement affiliates. Health.AI earns from optional Pro subscriptions to its AI tools. If that changes, this box changes first.
Demand the next dissection
Any disease, drug, supplement, or practice. The queue decides what we dissect next.